C. Diff - Xconomy

by in

Entry	Author	Date	Location
Optimer Inks Potential $47.5M-Plus Deal with Cubist to Help Sell Antibiotic	Ryan McBride	04/06/11	San Diego
Optimer Seeks Quick Green Light From FDA for Antibiotic Against Deadly Bug	Luke Timmerman	11/30/10	San Diego
Optimer Halts Study After Antibiotic for Traveler’s Diarrhea Linked to Rash; Shares Drop	Luke Timmerman	11/10/10	San Diego
Indel Therapeutics Aims High With New Class of Antibiotics to Fight Hospital Infections	Luke Timmerman	03/30/09	Seattle
Vioguard CEO Larry Ranta Takes Germ-Zapping Keyboard Into Growing Hospital Market	Gregory T. Huang	03/26/09	Seattle
Optimer Raises $32.9M in Stock Offering	Luke Timmerman	03/05/09	San Diego
Optimer’s Second Drug, for Traveler’s Diarrhea, Follows Fast Behind Lead “C. Diff” Antibiotic	Luke Timmerman	01/23/09	San Diego
Optimer Sharpens Up Commercial Game Plan, After “C.Diff” Drug Success	Luke Timmerman	12/05/08	San Diego
Navilyst Medical, Boston Scientific Spin-Off, Aiming to Tap Veins Without Causing Infections	Luke Timmerman	08/05/08	Boston
Page 1 of 1

Xconomy National